Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,347 result(s) found. Displaying page 1,228 of 2,218.
    EudraCT Number: 2008-007925-38 Sponsor Protocol Number: HE 4/09 Start Date*: 2009-04-07
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: STUDY OF THE mTOR INHIBITOR TEMSIROLIMUS (CCI-779) IN PATIENTS WITH CA125 ONLY RELAPSE OF OVARIAN CANCER A phase II study by the Hellenic Cooperative Oncology Group
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033128 Ovarian cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002364-13 Sponsor Protocol Number: M16VIB Start Date*: 2018-01-23
    Sponsor Name:Netherlands Cancer Institute- Antoni van Leeuwenhoek hospital (NKI-AVL)
    Full Title: MoTriColor: A phase II study of vinorelbine in advanced BRAF-like colon cancer
    Medical condition: colon carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006515-76 Sponsor Protocol Number: REO 011 Start Date*: 2007-01-08
    Sponsor Name:Oncolytics Biotech Inc
    Full Title: A Dose Targeted Phase I/II Study To Evaluate The Feasibility, Safety, And Biological Effects Of Intravenous Administration of A Wild-Type Reovirus (REOLYSIN®) in Combination With Paclitaxel and Car...
    Medical condition: Advanced or metastatic solid tumours that are refractory to standard therapy or for which no curative standard therapy exists and for which paclitaxel plus carboplatin is appropriate palliative che...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004314-15 Sponsor Protocol Number: SP015 Start Date*: 2016-11-16
    Sponsor Name:SOTIO a.s.
    Full Title: A phase I/II, single-arm clinical trial to evaluate the safety and immune activation of the combination of DCVAC/PCa, an active cellular immunotherapy, and ONCOS-102, an immune-priming adenovirus, ...
    Medical condition: advanced metastatic castration-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2013-002062-39 Sponsor Protocol Number: AOUMeyer#1 Start Date*: 2013-11-04
    Sponsor Name:Azienda Ospedaliero-Universitaria Meyer
    Full Title: Safety and efficacy of propranolol eye drops in neonates with retinopathy of prematurity: a pilot study (DROP-ROP).
    Medical condition: The medical condition to be investigated is Retinopathy of Prematurity (ROP)
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002069-21 Sponsor Protocol Number: D5180C00013 Start Date*: 2018-10-23
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults with Inadequately Controlled Asthma on Inhaled C...
    Medical condition: Severe Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020423-51 Sponsor Protocol Number: ETA0881X1-4718 Start Date*: 2011-02-17
    Sponsor Name:Asklepios Klinik Sankt Augustin
    Full Title: Remission Induction by Etanercept in Enthesitis related Arthritis JIA-Patients (juvenile undifferentiated Spondylarthropathy)
    Medical condition: Active enthesitis-related arthrtitis as a category of juvenile idiopathic arthritis (ERA-JIA) as determined by International League of Associations for Rheumatology (ILAR) criteria.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015516-18 Sponsor Protocol Number: 001 Start Date*: 2010-08-06
    Sponsor Name:Univ.-Klinik für Augenheilkunde und Optometrie, Medizinische Universität Wien
    Full Title: Microstructural morphological changes of the macula after intravitreal microplasmin for non-surgical treatment of vitreomacular traction syndrome
    Medical condition: Vitreomacular traction syndrome (VMTS) is a distinct clinical entity characterized by an incomplete separation of the posterior vitreous surface from the retina with persistent posterior hyaloid ad...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002771-33 Sponsor Protocol Number: ATX201-207 Start Date*: 2019-09-25
    Sponsor Name:UNION therapeutics A/S
    Full Title: A Randomized, Double-Blind, Parallel Group, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults with Mild to Moderate Atopic De...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-003089-34 Sponsor Protocol Number: HND-IM-011 Start Date*: 2011-09-06
    Sponsor Name:Chr. Hansen A/S
    Full Title: The effect for Lactobacillus paracasei subsp. paracasei, L. casei 431® on immune response to influenza vaccination in healthy adult volunteers - a multi-center, randomized, placebo-controlled, par...
    Medical condition: effect of probiotics on the immune response to seasonal influenza vaccination in healthy adults
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10016794 Flu vaccination LLT
    14.1 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    14.1 10042613 - Surgical and medical procedures 10046859 Vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002190-49 Sponsor Protocol Number: REO 008 Start Date*: 2006-11-08
    Sponsor Name:Oncolytics Biotech Inc
    Full Title: A Multi-Centre Single-Arm Phase II Study To Evaluate The Biological Effects Of Intratumoral Administration of Wild-Type Reovirus (REOLYSIN®) in Combination with Low Dose Radiation in Patients With ...
    Medical condition: Advanced or metastatic solid tumours that are refractory to standard therapy or for which no standard curative therapy exists
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-002588-14 Sponsor Protocol Number: APOTEL-02 Start Date*: 2014-09-22
    Sponsor Name:UNI-PHARMA SA
    Full Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE IV CLINICAL STUDY OF THE EFFICACY AND SAFETY OF A NEW FORMULATION OF PARACETAMOL FOR THE MANAGEMENT OF FEVER OF INFECTIOUS ORIGIN
    Medical condition: Fever due to infection of the upper respiratory tract, of the lower respiratory tract, acute pyelonephritis or of the skin and soft tissues.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10042613 - Surgical and medical procedures 10049541 Antipyresis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2014-002178-35 Sponsor Protocol Number: DC2014ELIX001 Start Date*: 2014-08-06
    Sponsor Name:VU University Medical Center
    Full Title: A phase 4, monocenter, randomized, open label, comparator-controlled, parallel-group, mechanistic intervention trial to assess the effect of 8-week treatment with the glucagon-like peptide-1 recept...
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003970-28 Sponsor Protocol Number: VX18-561-101 Start Date*: 2019-06-18
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002484-25 Sponsor Protocol Number: TAK-935-2002(OV935) Start Date*: 2019-04-29
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-935 (OV935) AS AN ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS WITH ...
    Medical condition: Epileptic Encephalitis: Dravet and Lennox Gastuat syndrome (LGS)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-004800-23 Sponsor Protocol Number: RG-17-241 Start Date*: 2018-06-12
    Sponsor Name:University of Birmingham
    Full Title: A comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in co...
    Medical condition: Acute Lymphoblastic Leukaemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-002123-15 Sponsor Protocol Number: GEICAM/2019-01 Start Date*: 2020-06-15
    Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)
    Full Title: Phase II, randomized, open-label, international, multicenter study to compare efficacy of standard chemotherapy vs. letrozole plus abemaciclib as neoadjuvant therapy in HR-positive/HER2-negative hi...
    Medical condition: High/intermediate risk hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative breast cancer patients with indication of neoadjuvant therapy
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000851-42 Sponsor Protocol Number: ID-084A201 Start Date*: 2018-07-27
    Sponsor Name:Idorsia Pharmaceuticals Ltd
    Full Title: A randomized, double-blind, placebo-controlled, 12-week treatment study to evaluate the effect of ACT-774312 in subjects with bilateral nasal polyposis
    Medical condition: Bilateral nasal polyposis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10028756 Nasal polyps PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000998-72 Sponsor Protocol Number: 4083-006 Start Date*: 2019-01-22
    Sponsor Name:Kyowa Kirin Co., Ltd.
    Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects with Moderate to Severe Atopic Dermatitis
    Medical condition: Moderate to Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020749-28 Sponsor Protocol Number: GETNE-1002 Start Date*: 2010-11-08
    Sponsor Name:Grupo Español de Tumores Neuroendocrinos (GETNE)
    Full Title: Ensayo clínico fase II, abierto, no controlado, multicéntrico de pazopanib en monoterapia para la determinación de actividad, seguridad y biomarcadores predictivos en pacientes con progresión de t...
    Medical condition: Pacientes con progresión de tumores neuroendocrinos (NET) avanzados/metastásicos
    Disease: Version SOC Term Classification Code Term Level
    13 10062476 Tumor neuroendocrino LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jul 07 09:29:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA